European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - natural fish oil, quantity: 1 g (equivalent: eicosapentaenoic acid, qty 180 mg; equivalent: docosahexaenoic acid, qty 120 mg) - capsule, soft - excipient ingredients: gelatin; glycerol; purified water - maintain/support healthy eye function ; maintain/support eye health ; maintain/support general health and wellbeing ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; helps enhance/promote healthy joint function ; maintain/support joint health ; decrease/reduce/relieve mild joint inflammation/swelling ; maintain/support joint mobility/flexibility ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support brain function ; maintain/support brain health ; maintain/support nervous system health ; maintain/support nervous system function ; decrease/reduce/relieve symptoms of mild eczema/dermatitis

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

natures choice pty ltd - natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - natural fish oil, quantity: 500 mg (equivalent: docosahexaenoic acid, qty 60 mg; equivalent: eicosapentaenoic acid, qty 90 mg) - capsule, soft - excipient ingredients: purified water; sunset yellow fcf; gelatin; lecithin; glycerol; d-alpha-tocopherol; sucralose; citric acid monohydrate; titanium dioxide; soya oil; flavour - helps maintain/support healthy eye development ; maintain/support healthy eye function ; maintain/support eye health ; helps maintain/support eye retina health ; maintain/support healthy eyesight/vision ; helps enhance/promote healthy growth and development ; maintain/support healthy growth and development ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support brain function ; maintain/support brain health ; maintain/support nervous system health ; maintain/support brain/central nervous system development ; maintain/support nervous system function ; support healthy emotional/mood balance

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's bio technology pty ltd - natural fish oil, quantity: 1 g (equivalent: docosahexaenoic acid, qty 120 mg; equivalent: eicosapentaenoic acid, qty 180 mg) - capsule, soft - excipient ingredients: d-alpha-tocopherol; gelatin; glycerol; purified water - helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; anti-inflammatory/relieve inflammation ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support brain function ; maintain/support brain health

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Australia - English - Department of Health (Therapeutic Goods Administration)

natural force ( aust) pty ltd - natural fish oil -